logo Hematology/Oncology Research Studies: Open for Enrollment Date: 10/22/18

Category: STEM CELL TRANSPLANTATION AND CELLULAR THERAPY

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease

NCT#/Phase: NCT03263559
Phase 2
IRB#: 2017-066
Description: This is a single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with SCD with strokes; and (2) adults with severe SCD.
Inclusion: Individuals who are between 5 - 15 years of age and who have had an overt stroke, a first-degree related haploidentical donor available and who do not have an HLA-matched sibling who is able and willing to donate bone marrow. Individuals with Hb SS or S-Beta-0 Thalassemia are included.
Enrollment Status: Open for enrollment
Sponsor: BMT-CTN, Medical College of Wisconsin
Principal Investigator(s): Mark Walters, MD
Contact(s): Marci Moriarty, RN (510-428-3385 x5396)
Julie Decaris (510-428-3385 x2739)
Study Link: https://clinicaltrials.gov/ct2/show/NCT03263559

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000